EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR
EPA:ALCOX (3/7/2025, 7:00:00 PM)
0.292
+0.01 (+1.74%)
The current stock price of ALCOX.PA is 0.292 EUR. In the past month the price decreased by -3.95%. In the past year, price decreased by -29.13%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca and currently employs 5 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
NICOX SA
Drakkar 2- Bat D, 2405 route des Dolines, CS 10313 Sophia Antipolis
Valbonne PACA FR
Employees: 28
Company Website: http://www.nicox.com
Investor Relations: https://www.nicox.com/investor-information/
Phone: 33497245300
The current stock price of ALCOX.PA is 0.292 EUR. The price increased by 1.74% in the last trading session.
The exchange symbol of NICOX SA is ALCOX and it is listed on the Euronext Paris - Matif exchange.
ALCOX.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALCOX.PA and the average price target is 1.02 EUR. This implies a price increase of 249.32% is expected in the next year compared to the current price of 0.292. Check the NICOX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NICOX SA (ALCOX.PA) has a market capitalization of 20.24M EUR. This makes ALCOX.PA a Nano Cap stock.
NICOX SA (ALCOX.PA) currently has 28 employees.
NICOX SA (ALCOX.PA) has a support level at 0.28 and a resistance level at 0.31. Check the full technical report for a detailed analysis of ALCOX.PA support and resistance levels.
The Revenue of NICOX SA (ALCOX.PA) is expected to grow by 33.68% in the next year. Check the estimates tab for more information on the ALCOX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALCOX.PA does not pay a dividend.
NICOX SA (ALCOX.PA) will report earnings on 2025-04-21.
NICOX SA (ALCOX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
ChartMill assigns a technical rating of 3 / 10 to ALCOX.PA. When comparing the yearly performance of all stocks, ALCOX.PA is a bad performer in the overall market: 89% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ALCOX.PA. ALCOX.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 70.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -21.1% | ||
ROE | -38.13% | ||
Debt/Equity | 0.4 |
ChartMill assigns a Buy % Consensus number of 84% to ALCOX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 22.2% and a revenue growth 33.68% for ALCOX.PA